What is the clinical evidence from this study?

Study design: Observational. Population: Cancer (n=412). Intervention: ≥2 drug-related problems vs. <2 drug-related problems. Primary outcome: 30-day all-cause hospital readmission (adjusted OR 3.42, 95% CI 1.87-6.26).

What question did this study set out to answer?

To assess the prevalence, patterns, and causes of drug-related problems in hospitalized adult cancer patients and evaluate their independent association with 30-day all-cause hospital readmission.

September 14, 2026Journal of Oncology Pharmacy Practice

Having ≥2 drug-related problems linked to ~242% higher 30-day readmission risk in hospitalized cancer patients.

Q: What are the key findings of this study?

Having ≥2 drug-related problems was independently associated with 30-day all-cause hospital readmission among hospitalized cancer patients (adjusted OR 3.42; 95% CI 1.87-6.26).

Q: What does this research mean for the field?

Having ≥2 drug-related problems is independently associated with a significantly higher risk of 30-day all-cause hospital readmission among hospitalized cancer patients. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To assess the prevalence, patterns, and causes of drug-related problems in hospitalized adult cancer patients and evaluate their independent association with 30-day all-cause hospital readmission.

View Full Paper

Ask AI

Bookmark

Why the study?

Drug-related problems are common among hospitalised cancer patients due to complex chemotherapy, polypharmacy, and treatment-related organ dysfunction, but their prevalence and association with readmission are unclear.

Population

412 hospitalised adult cancer patients receiving antineoplastic or supportive-care medication

Design

Prospective observational study at a tertiary care teaching hospital

Follow-up

30 days after discharge

Key result

Having ≥2 drug-related problems was independently associated with 30-day all-cause hospital readmission among hospitalized cancer patients (adjusted OR 3.42; 95% CI 1.87-6.26).

Authors

GRGopika Roshin GRGopika Roshin NMNisam Meladath

Discussion

Member takes

Overview

May warrant medication review in hospitalized cancer patients; leaves open whether interventions reduce readmissions.

Key Points

To assess the prevalence, patterns, and causes of drug-related problems in hospitalized adult cancer patients and evaluate their independent association with 30-day all-cause hospital readmission.
Conducted a 12-month prospective observational study enrolling 412 consecutive adult cancer patients (≥18 years) receiving antineoplastic or supportive-care medication in oncology wards at a tertiary care teaching hospital.
Identified drug-related problems using the Pharmaceutical Care Network Europe (PCNE) Classification System V9.1 through chart reviews, medication reconciliation, and ward rounds, following patients for 30 days post-discharge.
Among 386 patients completing follow-up, 69.4% (n=268) presented with at least one drug-related problem (517 total, mean 1.9 ± 1.2), primarily involving treatment effectiveness (38.5%) and treatment safety (33.7%).
Thirty-day all-cause readmission occurred in 18.4% (n=71) of patients and was independently associated with having ≥2 drug-related problems (adjusted OR 3.42, 95% CI 1.87–6.26) and polypharmacy (≥5 medications; adjusted OR 2.15, 95% CI 1.18–3.92).
Additional independent risk factors for 30-day readmission included an ECOG performance status ≥2 (adjusted OR 2.61, 95% CI 1.34–5.09) and the presence of a major drug interaction (adjusted OR 1.98, 95% CI 1.02–3.86).

Study Design

Type

Observational (n=412)

Multicenter

Structured PICO

Population

412 hospitalized adults with confirmed malignancy receiving antineoplastic or supportive-care medication, followed for 30 days after discharge.

Outcome

Prevalence, types, and causes of drug-related problems (DRPs) and 30-day all-cause hospital readmissionhard clinical

Main Result

Odds Ratio: 3.42 (95% CI 1.87–6.26)

Drug-related problems are highly prevalent in hospitalized cancer patients and are independently associated with an increased risk of 30-day hospital readmission.

Cite This Study

Roshin et al. (2026) conducted an observational in Cancer (n=412). ≥2 drug-related problems vs. <2 drug-related problems was evaluated on 30-day all-cause hospital readmission (adjusted OR 3.42, 95% CI 1.87-6.26). Having ≥2 drug-related problems was independently associated with 30-day all-cause hospital readmission among hospitalized cancer patients (adjusted OR 3.42; 95% CI 1.87-6.26).

synapsesocial.com/papers/6aa7afef79e9260bc85aad11 https://doi.org/10.1177/10781552261487990

View Full Paper

Ask AI

Bookmark

September 14, 2026Journal of Oncology Pharmacy Practice

Having ≥2 drug-related problems linked to ~242% higher 30-day readmission risk in hospitalized cancer patients.

View Full Paper

Ask AI

Bookmark

Why the study?

Population

412 hospitalised adult cancer patients receiving antineoplastic or supportive-care medication

Design

Prospective observational study at a tertiary care teaching hospital

Follow-up

30 days after discharge

Key result

Having ≥2 drug-related problems was independently associated with 30-day all-cause hospital readmission among hospitalized cancer patients (adjusted OR 3.42; 95% CI 1.87-6.26).

Authors

GRGopika Roshin GRGopika Roshin NMNisam Meladath

Discussion

Member takes

Overview

May warrant medication review in hospitalized cancer patients; leaves open whether interventions reduce readmissions.

Key Points

To assess the prevalence, patterns, and causes of drug-related problems in hospitalized adult cancer patients and evaluate their independent association with 30-day all-cause hospital readmission.
Conducted a 12-month prospective observational study enrolling 412 consecutive adult cancer patients (≥18 years) receiving antineoplastic or supportive-care medication in oncology wards at a tertiary care teaching hospital.
Identified drug-related problems using the Pharmaceutical Care Network Europe (PCNE) Classification System V9.1 through chart reviews, medication reconciliation, and ward rounds, following patients for 30 days post-discharge.
Among 386 patients completing follow-up, 69.4% (n=268) presented with at least one drug-related problem (517 total, mean 1.9 ± 1.2), primarily involving treatment effectiveness (38.5%) and treatment safety (33.7%).
Thirty-day all-cause readmission occurred in 18.4% (n=71) of patients and was independently associated with having ≥2 drug-related problems (adjusted OR 3.42, 95% CI 1.87–6.26) and polypharmacy (≥5 medications; adjusted OR 2.15, 95% CI 1.18–3.92).
Additional independent risk factors for 30-day readmission included an ECOG performance status ≥2 (adjusted OR 2.61, 95% CI 1.34–5.09) and the presence of a major drug interaction (adjusted OR 1.98, 95% CI 1.02–3.86).

Study Design

Type

Observational (n=412)

Multicenter

Structured PICO

Population

412 hospitalized adults with confirmed malignancy receiving antineoplastic or supportive-care medication, followed for 30 days after discharge.

Outcome

Prevalence, types, and causes of drug-related problems (DRPs) and 30-day all-cause hospital readmissionhard clinical

Main Result

Odds Ratio: 3.42 (95% CI 1.87–6.26)

Drug-related problems are highly prevalent in hospitalized cancer patients and are independently associated with an increased risk of 30-day hospital readmission.

Cite This Study

synapsesocial.com/papers/6aa7afef79e9260bc85aad11 https://doi.org/10.1177/10781552261487990

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark